Sold as Netspot. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Gallium Dotatate GA-68 (sold as Netspot), first approved Jun 1, 2016, with 0 new uses approved and 0 published complete response letters.
| Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudySystemic Lupus Erythematosus, Atherosclerosis Generalized · University of Cambridge | Not applicable | Recruiting | Nov 3, 2026 |
| Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver MetastasesGastroenteropancreatic Neuroendocrine Tumors · First Affiliated Hospital of Fujian Medical University | — | Recruiting | Oct 27, 2026 |
| Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseThyroid Eye Disease · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — | Recruiting | Sep 23, 2026 |
| 68Ga-NYM215 in NENsNeuroendocrine Neoplasms · Peking Union Medical College Hospital | Phase 1 / Phase 2 | Recruiting | Sep 23, 2026 |
| A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNeuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma · British Columbia Cancer Agency | — | Not yet recruiting | Jun 2, 2026 |
| Symptomatic and Systemic Atherosclerotic Plaque Activity in Patients With Peripheral Arterial Disease Using Novel ImagingPeripheral Arterial Disease, Chronic Limb Threatening Ischemia · University of Edinburgh | — | Recruiting | Mar 16, 2026 |
| Al18F-NOTA-LM3 PET/CT in Patients With TIOTumor-Induced Osteomalacia · Peking Union Medical College Hospital | Not applicable | Recruiting | Jan 26, 2026 |
| Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromeCushing s Syndrome · Peking Union Medical College Hospital | Phase 1 / Phase 2 | Recruiting | Jan 20, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA